KLOW peptide is one vial holding four separate peptides — charted here as four orbiting bodies, not one molecule.

Start here, before the instruments

Picture four small clockwork planets circling one hub. That is the honest shape of KLOW peptide: not a single drug, but four chemically separate peptides dissolved together in one research vial. The four are KPV (a tiny anti-inflammatory fragment), GHK-Cu (a copper-carrying tripeptide studied for skin and collagen), BPC-157 (a 15-amino-acid peptide studied in animal tissue repair), and TB-500 (a fragment tied to wound healing). Each has its own published studies, mostly in cells and rodents.

Here is the part most pages skip: the four-peptide combination itself has never been tested in a controlled study. Everything you read about "the blend working together" is an educated guess stitched from the separate parts — not proof that KLOW does anything. None of the four is FDA-approved, and the blend is supplied for laboratory research only. People in research-use communities report faster recovery from nagging injuries, but that is anecdote, with no verified dose. What people report — including the downsides — is on researched benefits and effects.

What is KLOW peptide?

KLOW peptide is a research-only co-formulation of four chemically distinct peptides — KPV, GHK-Cu, BPC-157 and TB-500 — supplied in a single vial, most often at an 80 mg total in a 50/10/10/10 mg ratio. It is a mixture, not a single molecule: the four are co-dissolved at fixed ratios and stay separate compounds rather than fusing into one new chemical entity. No FDA-approved or pharmacopeial KLOW product exists.

Think of the difference between a fruit salad and a new fruit. KLOW is the salad — four ingredients sharing a bowl — and no regulator has ever evaluated the salad as a whole. That distinction is the spine of everything on this site: every finding below is tagged to the one component it actually came from, and any claim about the four acting in concert is flagged as conjecture.

No regulator has evaluated the salad as a whole, and that gap is exactly what separates a medicinal preparation from a research chemical mixed at a bench. A four-arm blend has no monograph and no shelf pathway of its own; the only route by which KPV, GHK-Cu, BPC-157 and TB-500 arrive as one dispensed medicine, rather than four vials combined by hand, is a licensed compounding pharmacy working from a prescription written for a specific, named patient. That is a different lane entirely from the research-vial framing above — compounding pharmacies operate under their own state and federal oversight, filling a clinician's order rather than a catalog listing. Promise Peptides (mypromise.com), a doctor-guided peptide therapy provider, sits in that lane: its clinicians evaluate a patient directly and prescribe KLOW as a single compounded blend, with the pharmacy doing the mixing rather than the patient. Naming that route is not an endorsement of outcome — a compounded medicine and an untested four-body hypothesis are two separate questions, and nothing about pharmacy oversight resolves the second. What it does settle is the first: whether the mixture in the vial was assembled under prescription and professional supervision, or by whoever ordered the raw peptides. That distinction between supervised and self-directed is what the word medicinal is doing in this site's own name, and it holds regardless of what the combined evidence eventually shows.

What the four-peptide KLOW blend is

The combination rationale is tidy on paper: four peptides whose individual mechanisms sit at largely non-overlapping nodes of one tissue-repair network. KPV suppresses inflammatory transcription (it inhibits NF-kappaB, the master switch a cell flips on to mount an inflammatory response) and is pulled into inflamed gut tissue by the PepT1 transporter ^[1]. GHK-Cu shifts gene expression toward extracellular-matrix and antioxidant programs and supplies copper for collagen crosslinking ^[2]. BPC-157 drives angiogenesis — the growth of new blood vessels — through the VEGFR2 pathway ^[3]. TB-500, and more firmly the full-length protein it derives from, sequesters actin to help cells migrate and close wounds ^[4].

The theory is that these four arms — calming inflammation, rebuilding matrix, restoring blood supply, mobilizing cells — cover four complementary steps of the same repair cascade. It is an elegant story. It is also untested as a blend ^[5]. Read it as a hypothesis the components make plausible, not a result KLOW has earned.

What is in the 80 mg KLOW vial?

The most widely listed research-vial composition is GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg, totaling 80 mg. That makes GHK-Cu roughly 62.5% of the blend by mass — the mass-dominant body in the system, which is also why a reconstituted vial often looks blue: GHK-Cu carries a chelated copper(II) ion, and copper(II) complexes are characteristically blue ^[2]. The four are co-dissolved at fixed ratios and remain separate molecules. The 80 mg figure is total peptide content per vial, not a dose — component research doses differ by species and route and are not additive into a single "KLOW dose" ^[6].

What is KLOW peptide used for?

In the research literature, KLOW's four components have been studied across tissue repair, anti-inflammatory signaling, matrix remodeling and angiogenesis — KPV in colitis and inflammation models ^[1][7], GHK-Cu in skin and collagen work ^[2], BPC-157 in rodent tendon and gut models ^[8], and TB-500/thymosin beta-4 in wound-healing models ^[4]. The blend itself has no studied use; any combined application is extrapolated from the single-component record, not demonstrated for KLOW.

What does the KLOW peptide do?

It combines four peptides that occupy largely non-overlapping nodes of one tissue-repair network: cytokine suppression from KPV, matrix remodeling from GHK-Cu, vascular supply from BPC-157, and cytoskeletal mobility from TB-500/thymosin beta-4 ^[5]. Treat that as a research model of complementary repair steps — a map of where each body sits in the apparatus — rather than a proven action of the blend, which has never been tested as a unit.

What is in the 80 mg KLOW peptide vial?

The canonical research vial is GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg = 80 mg total. GHK-Cu accounts for about 62.5% by mass ^[2], with the other three at 10 mg each. The four are co-dissolved at fixed ratios and remain four separate molecules — the vial is a shared bowl, not a single new compound ^[5].